Aug 19, 2019
Last Posted: May 16, 2019
- Pharmacogenetics of Warfarin in a Diverse Patient Population.
Mak May et al. Journal of cardiovascular pharmacology and therapeutics 2019 May 1074248419843530 - Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System.
Kim Dong-Jin et al. Applied health economics and health policy 2017 Oct 15(5) 657-667 - Thrombin generation profile in non-thrombotic factor V Leiden carriers.
Billoir Paul et al. Journal of thrombosis and thrombolysis 2019 Apr 47(3) 473-477 - CLINGEN Actionability Report for Factor V Leiden, Homozygous (also includes compound heterozygous FVL + prothrombin G20210A) - F5
ClinGen Actionability Working Group - CLINGEN Actionability Report for Factor V Leiden, Heterozygous - F5
ClinGen Actionability Working Group - CLINGEN Actionability Report for Thrombophilia due to protein C deficiency - PROC
ClinGen Actionability Working Group - CLINGEN Actionability Report for Thrombophilia due to protein S deficiency - PROS1
ClinGen Actionability Working Group - CLINGEN Actionability Report for von Willebrand Disease - VWF
ClinGen Actionability Working Group - Deep vein thrombosis during long-term surveillance of patients with liver transplantation.
Balaceanu Alice et al. Irish journal of medical science 2019 Mar - Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Viswanathan Meera et al. JAMA 2018 Jun 319(24) 2532-2551
.png)
No hay comentarios:
Publicar un comentario